Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 5
Submit an article Journal homepage
108
Views
23
CrossRef citations to date
0
Altmetric
Drug Evaluation

Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders

Paolo Prandoni University of Padua, Department of Medical and Surgical Sciences, Thromboembolism Unit, Via Giustiniani, 2; 35128 – Padua, Italy +39 049 8212656; +39 049 8218731; [email protected]
,
Daniela Tormene University of Padua, Department of Medical and Surgical Sciences, Thromboembolism Unit, Via Giustiniani, 2; 35128 – Padua, Italy +39 049 8212656; +39 049 8218731; [email protected]
,
Marica Perlati University of Padua, Department of Medical and Surgical Sciences, Thromboembolism Unit, Via Giustiniani, 2; 35128 – Padua, Italy +39 049 8212656; +39 049 8218731; [email protected]
,
Barbara Brandolin University of Padua, Department of Medical and Surgical Sciences, Thromboembolism Unit, Via Giustiniani, 2; 35128 – Padua, Italy +39 049 8212656; +39 049 8218731; [email protected]
&
Luca Spiezia University of Padua, Department of Medical and Surgical Sciences, Thromboembolism Unit, Via Giustiniani, 2; 35128 – Padua, Italy +39 049 8212656; +39 049 8218731; [email protected]
Pages 773-777 | Published online: 30 Apr 2008

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Meng Qiao, Ruoyu Jiao, Xing Zhang, Zhengzhang Wu, Baoxing Shen & Bingzhi Li. (2020) 1H NMR analysis of perdeutero N-sulfoheparosan C5-epimerization: a direct way to measure the activity of immobilized C5-epimerase. Journal of Carbohydrate Chemistry 39:9, pages 437-449.
Read now
Job Harenberg. (2010) Idraparinux and idrabiotaparinux. Expert Review of Clinical Pharmacology 3:1, pages 9-16.
Read now

Articles from other publishers (21)

Supriya Dey, Hong-Jay Lo & Chi-Huey Wong. (2019) An Efficient Modular One-Pot Synthesis of Heparin-Based Anticoagulant Idraparinux. Journal of the American Chemical Society 141:26, pages 10309-10314.
Crossref
Shifaza Mohamed & Deirdre Coombe. (2017) Heparin Mimetics: Their Therapeutic Potential. Pharmaceuticals 10:4, pages 78.
Crossref
Kezhou Dong, Yanzhi Song, Xiaodong Li, Jie Ding, Zhiyong Gao, Daopei Lu & Yimin Zhu. (2016) Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database of Systematic Reviews 2016:10.
Crossref
Zhiyong Dong, Jing Xu, Zhen Wang & Maxim S Petrov. (2016) Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy. Cochrane Database of Systematic Reviews.
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs 428 432 .
Pierre-Alexandre Driguez, Pierre Potier & Patrick Trouilleux. (2014) Synthetic oligosaccharides as active pharmaceutical ingredients: Lessons learned from the full synthesis of one heparin derivative on a large scale. Natural Product Reports 31:8, pages 980.
Crossref
Yanzhi Song, Xiaodong Li, Settipalli Pavithra & Dong Li. (2013) Idraparinux or Idrabiotaparinux for Long-Term Venous Thromboembolism Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE 8:11, pages e78972.
Crossref
Elizabeth Yuriev & Paul RamslandNeha Gandhi & Ricardo Mancera. 2012. Structural Glycobiology. Structural Glycobiology 259 296 .
Stavros Apostolakis, Gregory YH Lip, Deirdre A Lane & Eduard Shantsila. (2011) The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. Cardiovascular Therapeutics 29:6, pages e12-e22.
Crossref
Béatrice Hechler, Monique Freund, Ghina Alame, Cécile Leguay, Sébastien Gaertner, Jean-Pierre Cazenave, Maurice Petitou & Christian Gachet. (2011) The Antithrombotic Activity of EP224283, a Neutralizable Dual Factor Xa Inhibitor/Glycoprotein IIbIIIa Antagonist, Exceeds That of the Coadministered Parent Compounds. Journal of Pharmacology and Experimental Therapeutics 338:2, pages 412-420.
Crossref
Jan Steffel & Eugene Braunwald. (2011) Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European Heart Journal 32:16, pages 1968-1976.
Crossref
Yu‐Kai Lee & Mark R. Player. (2011) Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. Medicinal Research Reviews 31:2, pages 202-283.
Crossref
Donald J. AbrahamBrian L. Henry & Umesh R. Desai. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 365 408 .
Kellie A Vavra, Mark F Lutz & Maureen A Smythe. (2017) Recombinant Factor VIIa to Manage Major Bleeding from Newer Parenteral Anticoagulants. Annals of Pharmacotherapy 44:4, pages 718-726.
Crossref
Karen S. Carlson & Maria T. DeSancho. (2010) Hematological Issues in Critically Ill Patients with Cancer. Critical Care Clinics 26:1, pages 107-132.
Crossref
J.K. Aronson. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions 617 663 .
Gunilla Fernlöf, Britta M Sjöström, Klas M Lindell & Ulrika E Wall. (2009) Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin. Blood Coagulation & Fibrinolysis 20:8, pages 667-674.
Crossref
Jan Steffel & Thomas F Lüscher. (2009) Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. Journal of Cardiovascular Medicine 10:8, pages 616-623.
Crossref
Chen Chen & Biao Yu. (2009) Efficient synthesis of Idraparinux, the anticoagulant pentasaccharide. Bioorganic & Medicinal Chemistry Letters 19:14, pages 3875-3879.
Crossref
Raffaele De Caterina, Steen Dalby Kristensen & Giulia Renda. (2009) New anticoagulants for atrial fibrillation. Journal of Cardiovascular Medicine 10:6, pages 446-453.
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.